Vir Biotechnology Inc.

NYSE: VIR
$33.14
-$0.86 (-2.5%)
Closing price January 20, 2022
Tuesday’s top analyst upgrades and downgrades included Bilibili, Carvana, Crocs, GameStop, Goldman Sachs, Nike, Sarepta Therapeutics, Vir Biotechnology and Weber.
Monday’s top analyst upgrades and downgrades included Bionano Genomics, CarMax, CNH Industrial, Global Payments, Infosys, Huya, JD.com, Oshkosh, Restaurant Brands International and WiPro.
Monday's top analyst upgrades and downgrades included Carnival, Five9, Knight-Swift, Las Vegas Sands, Norwegian Cruise Line, Paysafe, Warby Parker and Whirlpool.
Thursday's top analyst upgrades and downgrades included ADT, Chevron, Camping World, Costco, D.R. Horton, General Electric, Nio and Occidental Petroleum.
Wednesday's top analyst upgrades and downgrades included Applied Materials, Caterpillar, Costco Wholesale, JPMorgan, Spotify, Vertex Pharmaceutical, Vornado Realty Trust and Whiting Petroleum.
Wednesday's top analyst upgrades and downgrades included Alexion Pharmaceuticals, Amazon.com, Diageo, eBay, Etsy, Home Depot, MGIC Investment, Netflix, Sirius XM and Vir Biotechnology.
Vir Biotechnology shares jumped on Tuesday after the firm announced that it would be expanding its late-stage COVID-19 study in conjunction with GlaxoSmithKline.
24/7 Wall St. has tracked some health care companies with prospects at crafting a vaccine to deal with this novel coronavirus and where they stand now.
Friday's top analyst calls included Amazon, Adobe, AMD, Apple, BlackRock, Broadcom, Caterpillar, Deere, Microsoft, Morgan Stanley, Oracle and Slack.